Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

By Jack Cuzick, I. Šestak, M. Baum, A. Buzdar, A. Howell, Mitchell Dowsett, J. Forbes. The Lancet Oncology, 2010

1,542 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/7fc0deb562dcd4407295ae62bcc1433c984d246e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Jane E. Visvader

In Genetics

1. Jane E. Visvader

Citations in the corpus

• Risk Factors and Preventions of Breast Cancer (2017, background): “A 10-year ATAC trial study indicated fewer serious side-effects for anastrozole than for tamoxifen in postmenopausal women with early ER+ breast cancer [111].”
• Cells of origin in cancer (2011, background): “Tamoxifen and aromatase inhibitors (inhibitors of oestrogen action and biosynthesis, respectively) are the prototypes for chemopreventive agents in hormone-receptor-positive breast cancer, as they markedly reduce the rate of disease recurrence and more than halve the incidence of new cancers in pati”